tradingkey.logo
tradingkey.logo

Sanofi: Venglustat Earns Breakthrough Therapy Designation In U.S.

ReutersMar 18, 2026 6:05 AM

- Sanofi SA SASY.PA:

  • SANOFI’S VENGLUSTAT EARNS BREAKTHROUGH THERAPY DESIGNATION IN THE US FOR TYPE 3 GAUCHER DISEASE

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey

Recommended Articles

Tradingkey
KeyAI